Trevi Therapeutics Preparing for Stifel Healthcare Conference
On November 11, Trevi Therapeutics, Inc. (NASDAQ: TRVI) will participate in the Stifel 2025 Healthcare Conference, a pivotal event for health sector innovators. Jennifer Good, the company's President and CEO, along with James Cassella, Ph.D., their Chief Development Officer, will lead the discussions. This exciting fireside chat is scheduled for 3:20 p.m. ET and promises to provide significant insights into the company’s innovations and future prospects.
Fireside Chat Insights
The fireside chat will showcase Trevi’s revolutionary therapy Haduvio™ (oral nalbuphine ER), which is currently being designed to assist patients suffering from chronic cough due to idiopathic pulmonary fibrosis (IPF) and other chronic conditions. As leaders in the field, Ms. Good and Dr. Cassella will also engage in direct meetings with investors attending the Conference. This provides a valuable opportunity for stakeholders to learn more about ongoing research and advancements.
Understanding the Need for Haduvio
Chronic cough is more than just an inconvenience for many individuals; it’s a debilitating symptom for approximately 150,000 patients suffering from IPF in the U.S. alone. Of these patients, about two-thirds experience uncontrolled cough despite their condition. Moreover, with around 228,000 individuals diagnosed with non-IPF interstitial lung disease, up to 60% report similarly bothersome chronic coughs. Such statistics highlight the urgent need for effective therapies, showcasing the importance of Haduvio in the marketplace.
The Impact of Chronic Cough
Chronic cough can drastically affect a person's quality of life. Patients can cough as often as 1,500 times a day, creating issues not just physically but also psychologically and socially. This persistent symptom is linked to increased hospitalizations and worsening health outcomes. By targeting the cough reflex through a dual-action mechanism as a kappa agonist and a mu antagonist (KAMA), Haduvio seeks to fill a crucial gap in patient care.
Challenges Facing Patients with Refractory Chronic Cough
Refractory chronic cough (RCC) affects an estimated 2-3 million individuals in the U.S. and presents unique challenges as it often persists beyond 8 weeks, despite appropriate treatment for underlying conditions. Understanding the complexities of this condition reveals its association with cough reflex hypersensitivity, impacting physical and emotional well-being. Trevi is committed to addressing these challenges through ongoing clinical development.
Haduvio’s Development and Future Prospects
As Trevi Therapeutics continues to advance the study of Haduvio, the company’s innovative approach remains unassessed by regulatory bodies, leading to a growing excitement among patients and investors alike. Trevi Therapeutics aims to position Haduvio as the leading agent for chronic cough treatment, potentially transforming how this common yet often overlooked condition is managed.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering innovative therapies for chronic cough. Their primary focus is on Haduvio™, engineered specifically for patients with chronic cough related to IPF, non-IPF ILD, and RCC. Haduvio is currently the only investigational therapy that demonstrates a statistically significant reduction in cough frequency in relevant clinical studies.
Frequently Asked Questions
What is Haduvio?
Haduvio is an investigational medication designed to treat chronic cough in patients with specific lung conditions.
Why is Trevi participating in the Stifel Conference?
Trevi aims to showcase their innovative therapies and engage with investors regarding future opportunities.
What conditions does Haduvio target?
Haduvio is aimed at treating chronic cough related to idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough.
How prevalent is chronic cough in patients with IPF?
About two-thirds of IPF patients deal with uncontrolled chronic cough, highlighting a significant need for effective therapies.
What is the dual-action mechanism of Haduvio?
It acts both as a kappa agonist and a mu antagonist, targeting the central and peripheral nervous systems to manage cough reflexes.
